Dr. Cui's research has focused on the development of novel agents that can elicit developmental stage-specific gene silencing or reprogramming in hematopoietic stem cells and progenitors through a series of epigenetic chromatin modifications by nucleosome remodeling, histone deacetylation and demethylation. Such agents can be applied to the treatment of the patients with hematologic disorders such as sickle cell disease and beta-thalassemia, as well as acute myeloid leukemia (Blood cancer), which arise from congenital defects in genome. The findings from these preclinical studies could also help to establish therapeutic indications in other hematological malignancies.
Diversity, Equity, Inclusion and Accessibility
If you are not sure what is DEIA. Here are the definitions from https://www.bmc.org/glossary-culture-transformation.
Diversity: Each individual is unique, and groups of individuals reflect multiple dimensions of identity: race, sex and gender, socio-economic status, sexuality, age, ability, national origin, religious beliefs, cognitive styles, personality, appearance, and much more. Valuing diversity means embracing and celebrating the rich dimensions of difference that exist in groups and eliminating interpersonal and institutional biases based on these differences.
Equity: The state in which differences in life outcomes are not predicted by one’s race, sex and gender, and other dimensions of identity, with specific emphasis on populations bearing the burden of inequities (e.g., people of color, women, LGBTQIA+ individuals). Valuing equity means engaging those most impacted by structural inequity in the creation and implementation of institutional policies, practices, and messages that eliminate unfair differences in outcomes, so everyone has the means and opportunity to improve the quality of their lives. Equity is both a process and an outcome.
Equity does not mean equality. Although both aim to achieve fairness, an equality approach treats everyone the same regardless of need, while an equity approach treats people differently and appropriately dependent on need.
Inclusion: The fundamental and authentic integration of historically and currently excluded individuals and/or groups (e.g., Black, Indigenous, people of color, women, transgender and gender non-binary individuals, and the intersection of structurally marginalized identities) into positions, processes, activities, and decision and policy making in a way that shares power, values input and engenders belonging. In terms of understanding inclusion, we must understand who is excluded.
Accessibility: The "ability to access" the functionality of a system or entity, and gain the related benefits. The degree to which a product, service, or environment is accessible by as many people as possible. Accessible design ensures both direct (unassisted) access and indirect access through assistive technology (e.g., computer screen readers). Universal design ensures that an environment can be accessed, understood, and used to the greatest extent possible by all people.
I am deeply committed to develop and disseminate DEIA in the current academic environment.
I serve on the Diversity Equity Inclusion and Accessibility Committee and Anti-Racism Committee in the Department of Medicine, Section of Hematology and Medical Oncology to promote DEIA-related activities through recruiting and mentoring a diverse group of research fellows, graduate and undergrad students as well as creating and maintaining a DEIA work environment in the research laboratory.
I am also a member of Graduate Medical Sciences Awards Committee and Admissions Committee where I dedicate to improving DEIA activities.
Member
Boston University
Center of Excellence in Sickle Cell Disease
This tab shows grant data from BMC Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from BU Sponsored Research. It includes:
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data that did not automatically get imported into Profiles
from BU or BMC sources.
- Grant title
- Project period and this person’s role on the grant
- PI name, if this person is not the PI (the name will link if PI has a BU Profile)
- Funding source(s). An arrow indicates the flow of funding if multiple sponsors.
- Some grants will show an agency award/project number, and may be a link.
- Data is sorted by project end date, and updated monthly.
This tab shows grant data from the Boston VA. We are only showing grant title, and only for people in the role of PI.
Modulation of LSD1 and PGC-1a pathways by small molecule compounds for fetal hemoglobin induction09/01/2023 - 08/31/2025 (PI)
Doris Duke Charitable Foundation
Targeting PGC-1a for the treatment of sickle cell disease07/01/2022 - 05/31/2025 (PI)
National Heart, Lung, and Blood Institute/NIH/DHHS5R01HL155451-02
Inhibition of LSD1 by small molecule inhibitors stimulates fetal hemoglobin synthesis for sickle…09/01/2019 - 08/31/2024 (PI)
Doris Duke Charitable Foundation
LSD1 inhibition for the treatment of beta-globin disorders02/01/2021 - 08/31/2023 (PI)
Doris Duke Charitable Foundation
Interactions between fetal hemoglobin regulation networks07/01/2021 - 06/30/2023 (PI)
Doris Duke Charitable Foundation
Cui American Society of Hematology Junior Faculty Scholar Award in Basic/Translational Research07/01/2017 - 06/30/2019 (PI)
American Society of Hematology
Regulating transcriptional co-activator PGC-1a for the treatment of sickle cell disease05/12/2017 - 06/30/2018 (PI)
Pfizer, Inc
LSD1 Inhibition for the treatment of beta-globin disorders07/01/2016 - 06/30/2018 (PI)
American Heart Assoc
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
login
to make corrections and additions.
-
Sun Y, Habara A, Le CQ, Nguyen N, Chen R, Murphy GJ, Chui DHK, Steinberg MH, Cui S. Pharmacologic induction of PGC-1a stimulates fetal haemoglobin gene expression. Br J Haematol. 2022 Apr; 197(1):97-109.View Related Profiles. PMID: 35118652
-
Aygun B, Bello A, Thompson AA, Davis L, Sun Y, Luo HY, Cui S, Chui DHK. Clinical phenotypes of three children with sickle cell disease caused by HbS/Sicilian (dß)0 -thalassemia deletion. Am J Hematol. 2022 04; 97(4):E156-E158.View Related Profiles. PMID: 35045200; DOI: 10.1002/ajh.26470;
-
Li X, Chen M, Liu B, Lu P, Lv X, Zhao X, Cui S, Xu P, Nakamura Y, Kurita R, Chen B, Huang DCS, Liu DP, Liu M, Zhao Q. Transcriptional silencing of fetal hemoglobin expression by NonO. Nucleic Acids Res. 2021 09 27; 49(17):9711-9723. PMID: 34379783; PMCID: PMC8464040; DOI: 10.1093/nar/gkab671;
-
-
Tang B, Wang S, Wang SG, Wang HJ, Zhang JY, Cui SY. Invertebrate Trehalose-6-Phosphate Synthase Gene: Genetic Architecture, Biochemistry, Physiological Function, and Potential Applications. Front Physiol. 2018; 9:30. PMID: 29445344; PMCID: PMC5797772; DOI: 10.3389/fphys.2018.00030;
-
Morrison TA, Wilcox I, Luo HY, Farrell JJ, Kurita R, Nakamura Y, Murphy GJ, Cui S, Steinberg MH, Chui DHK. A long noncoding RNA from the HBS1L-MYB intergenic region on chr6q23 regulates human fetal hemoglobin expression. Blood Cells Mol Dis. 2018 03; 69:1-9.View Related Profiles. PMID: 29227829; PMCID: PMC5783741; DOI: 10.1016/j.bcmd.2017.11.003;
-
de Medeiros AS, Wyman AR, Alaamery MA, Allain C, Ivey FD, Wang L, Le H, Morken JP, Habara A, Le C, Cui S, Lerner A, Hoffman CS. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays. Cell Signal. 2017 Dec; 40:73-80.View Related Profiles. PMID: 28867658; PMCID: PMC5651194; DOI: 10.1016/j.cellsig.2017.08.011;
-
Jagadeeswaran R, Vazquez BA, Thiruppathi M, Ganesh BB, Ibanez V, Cui S, Engel JD, Diamond AM, Molokie RE, DeSimone J, Lavelle D, Rivers A. Pharmacological inhibition of LSD1 and mTOR reduces mitochondrial retention and associated ROS levels in the red blood cells of sickle cell disease. Exp Hematol. 2017 06; 50:46-52. PMID: 28238805; PMCID: PMC6263958; DOI: 10.1016/j.exphem.2017.02.003;
-
Cui S, Engel JD. Reactivation of Fetal Hemoglobin for Treating ß-Thalassemia and Sickle Cell Disease. Adv Exp Med Biol. 2017; 1013:177-202. PMID: 29127681; DOI: 10.1007/978-1-4939-7299-9_7;
-
Ibanez V, Vaitkus K, Rivers A, Molokie R, Cui S, Engel JD, DeSimone J, Lavelle D. Efficacy and safety of long-term RN-1 treatment to increase HbF in baboons. Blood. 2017 01 12; 129(2):260-263. PMID: 27908882; PMCID: PMC5234223; DOI: 10.1182/blood-2016-10-746727;
Showing 10 of 25 results.
Show More
-
Dai Y, Sangerman J, Nouraie M, Faller AD, Oneal P, Rock A, Owoyemi O, Niu X, Nekhai S, Maharaj D, Cui S, Taylor R, Steinberg M, Perrine S. Effects of hydroxyurea on F-cells in sickle cell disease and potential impact of a second fetal globin inducer. Am J Hematol. 2017 Jan; 92(1):E10-E11.View Related Profiles. PMID: 27766663; PMCID: PMC5167623; DOI: 10.1002/ajh.24590;
-
Rivers A, Vaitkus K, Ibanez V, Ruiz MA, Jagadeeswaran R, Saunthararajah Y, Cui S, Engel JD, DeSimone J, Lavelle D. The LSD1 inhibitor RN-1 recapitulates the fetal pattern of hemoglobin synthesis in baboons (P. anubis). Haematologica. 2016 Jun; 101(6):688-97. PMID: 26858356; PMCID: PMC5013966; DOI: 10.3324/haematol.2015.140749;
-
White JC, Pawar A, Fu G, Cui S, Tavernier F, Hamid M, Harro D, Giacherio D, Campbell AD, Hines PC. TR2/TR4 overexpression in a humanized sickle cell disease mouse model decreases RBC adhesion to VCAM-1. Blood Cells Mol Dis. 2015 Dec; 55(4):316-7. PMID: 26460253; PMCID: PMC7363477; DOI: 10.1016/j.bcmd.2015.07.003;
-
Cui S, Lim KC, Shi L, Lee M, Jearawiriyapaisarn N, Myers G, Campbell A, Harro D, Iwase S, Trievel RC, Rivers A, DeSimone J, Lavelle D, Saunthararajah Y, Engel JD. The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice. Blood. 2015 Jul 16; 126(3):386-96. PMID: 26031919; PMCID: PMC4504950; DOI: 10.1182/blood-2015-02-626259;
-
Cui S, Tanabe O, Sierant M, Shi L, Campbell A, Lim KC, Engel JD. Compound loss of function of nuclear receptors Tr2 and Tr4 leads to induction of murine embryonic ß-type globin genes. Blood. 2015 Feb 26; 125(9):1477-87. PMID: 25561507; PMCID: PMC4342359; DOI: 10.1182/blood-2014-10-605022;
-
Shi L, Sierant MC, Gurdziel K, Zhu F, Cui S, Kolodziej KE, Strouboulis J, Guan Y, Tanabe O, Lim KC, Engel JD. Biased, non-equivalent gene-proximal and -distal binding motifs of orphan nuclear receptor TR4 in primary human erythroid cells. PLoS Genet. 2014 May; 10(5):e1004339. PMID: 24811540; PMCID: PMC4014424; DOI: 10.1371/journal.pgen.1004339;
-
Shi L, Lin YH, Sierant MC, Zhu F, Cui S, Guan Y, Sartor MA, Tanabe O, Lim KC, Engel JD. Developmental transcriptome analysis of human erythropoiesis. Hum Mol Genet. 2014 Sep 01; 23(17):4528-42. PMID: 24781209; PMCID: PMC4119405; DOI: 10.1093/hmg/ddu167;
-
Cui S, Tanabe O, Lim KC, Xu HE, Zhou XE, Lin JD, Shi L, Schmidt L, Campbell A, Shimizu R, Yamamoto M, Engel JD. PGC-1 coactivator activity is required for murine erythropoiesis. Mol Cell Biol. 2014 Jun; 34(11):1956-65. PMID: 24662048; PMCID: PMC4019057; DOI: 10.1128/MCB.00247-14;
-
Shi L, Cui S, Engel JD, Tanabe O. Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction. Nat Med. 2013 Mar; 19(3):291-4. PMID: 23416702; PMCID: PMC5512162; DOI: 10.1038/nm.3101;
-
Campbell AD, Cui S, Shi L, Urbonya R, Mathias A, Bradley K, Bonsu KO, Douglas RR, Halford B, Schmidt L, Harro D, Giacherio D, Tanimoto K, Tanabe O, Engel JD. Forced TR2/TR4 expression in sickle cell disease mice confers enhanced fetal hemoglobin synthesis and alleviated disease phenotypes. Proc Natl Acad Sci U S A. 2011 Nov 15; 108(46):18808-13. PMID: 22042865; PMCID: PMC3219144; DOI: 10.1073/pnas.1104964108;
-
Cui S, Kolodziej KE, Obara N, Amaral-Psarris A, Demmers J, Shi L, Engel JD, Grosveld F, Strouboulis J, Tanabe O. Nuclear receptors TR2 and TR4 recruit multiple epigenetic transcriptional corepressors that associate specifically with the embryonic ß-type globin promoters in differentiated adult erythroid cells. Mol Cell Biol. 2011 Aug; 31(16):3298-311. PMID: 21670149; PMCID: PMC3147791; DOI: 10.1128/MCB.05310-11;
-
Zhang Y, Sandy AR, Wang J, Radojcic V, Shan GT, Tran IT, Friedman A, Kato K, He S, Cui S, Hexner E, Frank DM, Emerson SG, Pear WS, Maillard I. Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease. Blood. 2011 Jan 06; 117(1):299-308. PMID: 20870902; PMCID: PMC3037751; DOI: 10.1182/blood-2010-03-271940;
-
Kato K, Cui S, Kuick R, Mineishi S, Hexner E, Ferrara JL, Emerson SG, Zhang Y. Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease. Biol Blood Marrow Transplant. 2010 Jun; 16(6):751-71. PMID: 20116439; PMCID: PMC2913321; DOI: 10.1016/j.bbmt.2010.01.012;
-
Cui SY, Zhang WQ, Xu WH. Spatial and temporal expression of N-ethylmaleimide-sensitive factor gene in the nervous system of the cotton bollworm, Helicoverpa armigera. Insect Biochem Mol Biol. 2006 Jul; 36(7):603-9. PMID: 16835026; DOI: 10.1016/j.ibmb.2006.05.004;
-
Cui SY, Xu WH. Molecular characterization and functional distribution of N-ethylmaleimide-sensitive factor in Helicoverpa armigera. Peptides. 2006 Jun; 27(6):1226-34. PMID: 16386334; DOI: 10.1016/j.peptides.2005.11.011;
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.
| Year | Publications |
|---|
| 2005 | 1 |
| 2006 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 2 |
2023-2024 Boston University Chobanian & Avedisian School of Medicine:
Wing Tat Lee Awards
2023-2026 Doris Duke Charitable Foundation:
Sickle Cell Disease/Advancing Cures Award
2019-2022 Doris Duke Charitable Foundation:
Sickle Cell Disease/Advancing Cures Award
2017-2018 American Society of Hematology:
Scholar Awards
2017-2018 Pfizer:
ASPIRE US Sickle Cell Disease Competitive Research Awards
2013-2017 American Heart Association:
Award for National Scientist Development Grant
Available to Mentor as: (Review Mentor Role Definitions):
-
Advisor
-
Career Mentor
-
Co-Mentor or Peer Mentor
-
Diversity Mentor
-
Education Mentor
-
Project Mentor
-
Research / Scholarly Mentor
-
Work / Life Integration Mentor